Home/Filings/4/0000921895-25-001910

4//SEC Filing

BIOTECHNOLOGY VALUE FUND L P 4

Accession 0000921895-25-001910

CIK 0001815442other

View on SEC.gov Company Profile

Filed

Jun 30, 8:00 PM ET

Accepted

Jul 1, 6:41 PM ET

Size

45.1 KB

Accession

0000921895-25-001910

Insider Transaction Report

Form 4

Period: 2025-06-25

Kymera Therapeutics, Inc.KYMR

BIOTECHNOLOGY VALUE FUND II LP

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000

BVF II GP LLC

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000

Biotechnology Value Trading Fund OS LP

DirectorOther

Transactions

Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000

BVF Partners OS Ltd.

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425

BVF INC/IL

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733

BIOTECHNOLOGY VALUE FUND L P

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000

BVF I GP LLC

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000

BVF GP HOLDINGS LLC

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425

BVF PARTNERS L P/IL

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063

LAMPERT MARK N

DirectorOther

Transactions

Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+58,780$2,586,320→ 353,412 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+142,604$6,274,576→ 2,798,795 total
Purchase
Common Stock, $0.0001 par value
2025-06-30$44.00/sh+115,783$5,094,452→ 2,219,858 total
Award
Stock Option (Right to Buy)
2025-06-25+16,000→ 16,000 total(indirect: See footnote)
Exercise: $46.47Exp: 2035-06-24→ Common Stock, $0.0001 par value (16,000 underlying)

Holdings

Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (156,742 underlying)
156,742
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (52,733 underlying)
52,733
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $49.10Exp: 2031-06-15→ Common Stock, $0.0001 par value (20,063 underlying)
20,063
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $14.18Exp: 2032-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $27.67Exp: 2033-06-14→ Common Stock, $0.0001 par value (12,000 underlying)
12,000
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (201,546 underlying)
201,546
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (550,425 underlying)
550,425
Pre-Funded Warrants to Purchase Common Stock
Exercise: $0.00→ Common Stock, $0.0001 par value (375,856 underlying)
375,856
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $31.20Exp: 2034-06-17→ Common Stock, $0.0001 par value (16,000 underlying)
16,000
Stock Option (Right to Buy)
(indirect: See footnote)
Exercise: $20.00Exp: 2030-08-19→ Common Stock, $0.0001 par value (40,127 underlying)
40,127

Footnotes (9)

[F1]This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
[F2]Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
[F3]Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
[F4]Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
[F5]Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
[F6]Shares of the Issuer's common stock acquired in the Issuer's underwritten public offering at the public offering price of $44.00 per share.
[F7]The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders.
[F8]The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to certain conditions and limitations, and do not expire.
[F9]The shares subject to the option have fully vested.

Documents

1 file

4
form407422010_07012025.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

→

Entity typeother

IncorporatedDE

Related Parties

filerCIK 0000918923

Filing Metadata

Form type: 4
Filed: Jun 30, 8:00 PM ET
Accepted: Jul 1, 6:41 PM ET
Size: 45.1 KB

View on SEC.gov